Home / TIL : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does TIL make money? Does TIL have pricing power? What's the Earnings Whisper? Will TIL profit more as the business scales? What is TIL's management track record? Is TIL's current price justified?

Instil Bio, Inc.

$7.38 -$3.89 (-34.52%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$7.36

Day Range

$7.32$7.67

Year Range

$5.67$25.89

Market Cap

50.05M

AVG Volume

19.03K

Trailing/Forward PE

-1.65/-

PEG ratio

-0

Dividend Yield

Next Earnings Date

2026-11-16

Primary Exchange

NASDAQ

Revenue (USD) · TTM

TIL Revenue (USD) · TTM by quarter
Period	Revenue (USD) · TTM
26 Q2	0
26 Q1	0
25 Q4	0
25 Q3	0
25 Q2	0
25 Q1	0
24 Q4	0
24 Q3	0
24 Q2	0
24 Q1	0

Net Income (USD) · TTM

TIL Net Income (USD) · TTM by quarter
Period	Net Income (USD) · TTM
26 Q2	-30.28M
26 Q1	-47.38M
25 Q4	-71.37M
25 Q3	-75.08M
25 Q2	-84.51M
25 Q1	-78.03M
24 Q4	-74.14M
24 Q3	-75.17M
24 Q2	-119.58M
24 Q1	-123.32M

Operating Income (USD) · TTM

TIL Operating Income (USD) · TTM by quarter
Period	Operating Income (USD) · TTM
26 Q2	-36.18M
26 Q1	-54.04M
25 Q4	-78.58M
25 Q3	-80.5M
25 Q2	-89.11M
25 Q1	-79.8M
24 Q4	-68.92M
24 Q3	-70.3M
24 Q2	-113.39M
24 Q1	-120.24M

EBITDA (USD) · TTM

TIL EBITDA (USD) · TTM by quarter
Period	EBITDA (USD) · TTM
26 Q2	-29.61M
26 Q1	-41.59M
25 Q4	-65.77M
25 Q3	-66.93M
25 Q2	-75.29M
25 Q1	-67.44M
24 Q4	-62.2M
24 Q3	-63.54M
24 Q2	-107.91M
24 Q1	-113.04M

Cash Flows (USD) · TTM

TIL Cash Flows (USD) · TTM by quarter
Period	Cash Flows (USD) · TTM
26 Q2	-23.61M
26 Q1	-33.76M
25 Q4	-36.62M
25 Q3	-40.1M
25 Q2	-49.68M
25 Q1	-45.5M
24 Q4	-55.7M
24 Q3	-58.58M
24 Q2	-58.03M
24 Q1	-73.95M

EPS (USD) · TTM

TIL EPS (USD) · TTM by quarter
Period	EPS (USD) · TTM
26 Q2	-4.47
26 Q1	-7.08
25 Q4	-10.78
25 Q3	-11.39
25 Q2	-12.92
25 Q1	-11.97
24 Q4	-11.39
24 Q3	-11.56
24 Q2	-18.39
24 Q1	-18.97

Expenses (USD) · TTM

TIL Expenses (USD) · TTM by quarter
Period	Expenses (USD) · TTM
26 Q2	36M
26 Q1	43.5M
25 Q4	51.96M
25 Q3	53.13M
25 Q2	49.38M
25 Q1	50.11M
24 Q4	54.31M
24 Q3	55.46M
24 Q2	69.78M
24 Q1	83.11M

Shares Outstanding · TTM

TIL Shares Outstanding · TTM by quarter
Period	Shares Outstanding · TTM
26 Q2	-5.39M
26 Q1	-6.18M
25 Q4	-8.69M
25 Q3	-11.59M
25 Q2	-13.89M
25 Q1	-16.24M
24 Q4	-17.26M
24 Q3	-17.31M
24 Q2	-17.91M
24 Q1	-18.15M

Employee Count

TIL Employee Count by quarter
Period	Employee Count
2025	17
2024	14
2023	49
2022	192
2021	412

Free Cash Flow Yield

TIL Free Cash Flow Yield by quarter
Period	Free Cash Flow Yield
Sep 26	-47.18%
Sep 26	-45.93%
Aug 26	-45.93%
Aug 26	-45.93%
Aug 26	-47.18%
Aug 26	-67.18%
Jul 26	-69.92%
Jul 26	-69.82%
Jul 26	-67.09%
Jul 26	-64.65%
Jul 26	-64.4%
Jun 26	-67%
Jun 26	-66.37%
Jun 26	-62.85%
Jun 26	-61.69%
May 26	-61.69%
May 26	-60.86%
May 26	-61.69%
May 26	-66.17%
May 26	-68.35%
Apr 26	-66.99%
Apr 26	-60.8%
Apr 26	-66.58%
Apr 26	-67.24%
Mar 26	-69.31%
Mar 26	-69.41%
Mar 26	-71.84%
Mar 26	-66.9%
Feb 26	-66.68%
Feb 26	-64.78%
Feb 26	-74.27%
Feb 26	-76.47%
Jan 26	-84.05%
Jan 26	-83.11%
Jan 26	-83.94%
Jan 26	-83.23%
Jan 26	-52.66%
Dec 25	-52.47%
Dec 25	-52.66%
Dec 25	-54.74%
Dec 25	-54.34%
Nov 25	-46.51%
Nov 25	-45.16%
Nov 25	-41.15%
Nov 25	-49.9%
Oct 25	-42.69%
Oct 25	-38.82%
Oct 25	-39.45%
Oct 25	-39.16%
Oct 25	-41.6%
Sep 25	-44.48%
Sep 25	-37.78%
Sep 25	-31.25%
Sep 25	-23.91%
Aug 25	-27.89%
Aug 25	-27.9%
Aug 25	-27.05%
Aug 25	-24.88%
Aug 25	-31.33%
Jul 25	-21.98%
Jul 25	-26.69%
Jul 25	-28.44%
Jul 25	-25.33%
Jun 25	-30.32%
Jun 25	-25.14%
Jun 25	-20.35%
Jun 25	-21.18%
May 25	-25.84%
May 25	-33.13%
May 25	-47.61%
May 25	-64.51%
May 25	-58.94%
Apr 25	-66.78%
Apr 25	-55.2%
Apr 25	-56.78%
Apr 25	-58.42%
Mar 25	-47.2%
Mar 25	-47.71%
Mar 25	-42.93%
Mar 25	-46.61%
Feb 25	-44.79%
Feb 25	-40.7%
Feb 25	-39.12%
Feb 25	-43.22%
Jan 25	-40.44%
Jan 25	-38.41%
Jan 25	-42.93%
Jan 25	-45.35%
Jan 25	-43.68%
Dec 24	-44.9%
Dec 24	-43.68%
Dec 24	-40.98%
Dec 24	-32.42%
Nov 24	-33.45%
Nov 24	-34.43%
Nov 24	-33.97%
Nov 24	-28.93%
Nov 24	-31%
Oct 24	-28.72%
Oct 24	-23.82%

Price to Sales

TIL Price to Sales by quarter
Period	Price to Sales
Nov 21	51200.15
Nov 21	54072.11
Oct 21	50432.64
Oct 21	45084.85
Oct 21	44366.86
Oct 21	44441.13
Oct 21	47337.85
Sep 21	57166.9
Sep 21	48922.39
Sep 21	46223.73
Sep 21	53180.81
Aug 21	49491.83
Aug 21	41371.11
Aug 21	40925.46
Aug 21	23433.99
Jul 21	20612.6
Jul 21	26597.78
Jul 21	25885.58
Jul 21	27364.76
Jul 21	27501.72
Jun 21	26022.55
Jun 21	24680.33
Jun 21	23283.33
Jun 21	21311.1
May 21	24379.02
May 21	25214.48
May 21	24652.94
May 21	17605.96
Apr 21	19073.89
Apr 21	15459.79
Apr 21	17652.41
Apr 21	20467.5
Apr 21	22009.77
Mar 21	25140.75
Mar 21	24564.72

Price to Book

TIL Price to Book by quarter
Period	Price to Book
Sep 26	0.47
Sep 26	0.48
Aug 26	0.48
Aug 26	0.48
Aug 26	0.47
Aug 26	0.45
Jul 26	0.44
Jul 26	0.44
Jul 26	0.45
Jul 26	0.47
Jul 26	0.47
Jun 26	0.46
Jun 26	0.46
Jun 26	0.49
Jun 26	0.49
May 26	0.49
May 26	0.5
May 26	0.49
May 26	0.49
May 26	0.47
Apr 26	0.48
Apr 26	0.53
Apr 26	0.48
Apr 26	0.48
Mar 26	0.46
Mar 26	0.48
Mar 26	0.46
Mar 26	0.5
Feb 26	0.5
Feb 26	0.51
Feb 26	0.45
Feb 26	0.44
Jan 26	0.4
Jan 26	0.4
Jan 26	0.4
Jan 26	0.4
Jan 26	0.63
Dec 25	0.63
Dec 25	0.63
Dec 25	0.61
Dec 25	0.61
Nov 25	0.72
Nov 25	0.74
Nov 25	0.81
Nov 25	0.76
Oct 25	0.88
Oct 25	0.97
Oct 25	0.96
Oct 25	0.96
Oct 25	0.91
Sep 25	0.85
Sep 25	1
Sep 25	1.21
Sep 25	1.58
Aug 25	1.35
Aug 25	1.35
Aug 25	1.39
Aug 25	1.26
Aug 25	1
Jul 25	1.43
Jul 25	1.18
Jul 25	1.1
Jul 25	1.24
Jun 25	1.04
Jun 25	1.25
Jun 25	1.54
Jun 25	1.48
May 25	1.21
May 25	0.95
May 25	0.66
May 25	0.51
May 25	0.56
Apr 25	0.49
Apr 25	0.6
Apr 25	0.58
Apr 25	0.56
Mar 25	0.7
Mar 25	0.69
Mar 25	0.77
Mar 25	0.71
Feb 25	0.74
Feb 25	0.82
Feb 25	0.85
Feb 25	0.77
Jan 25	0.82
Jan 25	0.86
Jan 25	0.77
Jan 25	0.73
Jan 25	0.76
Dec 24	0.74
Dec 24	0.76
Dec 24	0.81
Dec 24	1.02
Nov 24	0.99
Nov 24	0.96
Nov 24	0.98
Nov 24	1.03
Nov 24	0.96
Oct 24	1.04
Oct 24	1.25

No video analysis for this stock yet. Request one from our team.

News: TIL

zacks.com · 26 Aug 2026

5 Biotech Stocks Worth Adding to Your Portfolio Now

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.

globenewswire.com · 13 Aug 2026

Instil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

DALLAS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a biotechnology company focused on identifying and advancing innovative therapeutics, today reported its second quarter 2026 financial results and provided a corporate update. Recent Highlights: Instil is evaluating potential acquisitions, in-licensing and related opportunities that may provide access to promising novel therapeutic candidates.

gurufocus.com · 3 Aug 2026

Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million

Obsidian Therapeutics, Inc. (âObsidianâ) (Nasdaq: OBX), a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop

seekingalpha.com · 16 Jul 2026

Iovance: The Worst May Be Behind This TIL Pioneer (Upgrading To Buy)

Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculative Buy rating upgrade. Q1 revenue reached $71.4M, with Amtagvi generating $60M; the sequential dip was attributed to one-off events, not demand weakness. Gross margin was impacted by temporary costs but is expected to improve to 50%+ as internal manufacturing scales and opex reductions take effect.